Skip to main
TBPH

TBPH Stock Forecast & Price Target

TBPH Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Theravance Biopharma is expected to see increased value through its acquisition by Zymeworks, which will likely result in a boost to the company's share price. Their YUPELRI product continues to perform well, with increasing sales and strong margins, and their IP has been secured through 2039. The company is also restructuring, which is expected to lead to further improvements in cash flow.

Bears say

Theravance Biopharma is currently facing several challenges, including the failure of its Phase 3 clinical study for ampreloxetine, competition in the market for its FDA-approved medicine YUPELRI, and potential financial risks due to its restructuring efforts. Additionally, the company's ongoing strategic review process and potential sale could also negatively impact its stock value and cash position in the near term.

TBPH has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Theravance Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Theravance Biopharma Inc (TBPH) Forecast

Analysts have given TBPH a Buy based on their latest research and market trends.

According to 5 analysts, TBPH has a Buy consensus rating as of Oct 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Theravance Biopharma Inc (TBPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.